{"id":"5-methoxypsoralen","safety":{"commonSideEffects":[{"rate":null,"effect":"Phototoxicity (erythema, blistering)"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased risk of skin cancer with chronic use"}]},"_chembl":{"chemblId":"CHEMBL1934197","moleculeType":"Small molecule","molecularWeight":"368.43"},"_fixedAt":"2026-03-30T17:36:42.070591","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-Methoxypsoralen (bergapten) is a naturally occurring furocoumarin that acts as a photosensitizing agent. When activated by long-wave ultraviolet A (UVA) radiation, it binds to DNA and creates interstrand crosslinks, leading to cell cycle arrest and programmed cell death. This mechanism is exploited therapeutically in photochemotherapy (PUVA therapy) for treating cutaneous T-cell lymphomas and other dermatological conditions.","oneSentence":"5-Methoxypsoralen is a photoactive compound that intercalates into DNA and forms covalent crosslinks upon UVA exposure, inducing apoptosis in abnormal cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:57:48.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Psoriasis"},{"name":"Vitiligo"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT03512756","phase":"PHASE2, PHASE3","title":"A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Tyme, Inc","startDate":"2018-03-27","conditions":"Pancreatic Cancer","enrollment":130},{"nctId":"NCT05882331","phase":"NA","title":"Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19","status":"COMPLETED","sponsor":"Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases","startDate":"2021-01-01","conditions":"COVID-19","enrollment":7},{"nctId":"NCT03109353","phase":"PHASE1, PHASE2","title":"Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2017-09-20","conditions":"Cutaneous T-Cell Lymphoma, Unspecified, Chronic Graft Versus Host Disease in Skin","enrollment":7},{"nctId":"NCT02524847","phase":"PHASE3","title":"Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease","status":"TERMINATED","sponsor":"Therakos, Inc., a Mallinckrodt Company","startDate":"2016-01-20","conditions":"Steroid Refractory Acute Graft Versus Host Disease","enrollment":29},{"nctId":"NCT00005092","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-05-28","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":7},{"nctId":"NCT00282503","phase":"PHASE3","title":"Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2006-01","conditions":"Acute Graft-versus-Host Disease","enrollment":19},{"nctId":"NCT02631993","phase":"","title":"Photochemotherapy and Graft-versus-leukemia in Acute-leukemia","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2014-10","conditions":"ALL, AML, Acute GVHD","enrollment":47},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":"Pustular Palmoplantar Psoriasis","enrollment":20},{"nctId":"NCT00533195","phase":"PHASE3","title":"Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Atopic Dermatitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"LEUKOPENIA"},{"count":1,"reaction":"NEUTROPENIA"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":320,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["5-MOP, Geralen"],"phase":"phase_3","status":"active","brandName":"5-Methoxypsoralen","genericName":"5-Methoxypsoralen","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-Methoxypsoralen is a photoactive compound that intercalates into DNA and forms covalent crosslinks upon UVA exposure, inducing apoptosis in abnormal cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Psoriasis, Vitiligo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}